Additionally, certain medications commonly used in T2DM, such as SGLT2 inhibitors, were studied for their potential impact on renal glucose handling, which could inadvertently affect the urinary environment in a way that reduces UTI risk. This evidence concerns the gene SLC5A2 and bacterial urinary tract infection.